JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB141248

Docetaxel, Cytotoxic agent

Docetaxel, Cytotoxic agent

Be the first to review this product! Submit a review

|

(4 Publications)

MW 807.9 Da, Purity >99%. Potent cytotoxic agent in vitro (IC50 = 2 nM). Disrupts microtubule assembly and arrests cell divison at G2/M phase. Induces apoptosis. Antitumor agent. Active in vivo and in vitro.

別名を表示する

ABC member 16, MDR/TAP subfamily, ABC16, ABCB1, ABCBB_HUMAN, ACUG, AI838772, AIS, ANDR_HUMAN, AR, AR8, ATP binding cassette sub family B (MDR/TAP) member 11, ATP-binding cassette sub-family B member 11, AW493413, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor, testicular feminization, spinal and bulbar muscular atrophy, Kennedy disease), Antigen NY-CO-13, Arthrocutaneouveal granulomatosis, Atherosclerosis, susceptibility to, included, BCC7, BLAU, BRIC2, Bile salt export pump, Bsep, CAR, CAR BETA, CARA, CARD15, CD, CLR16.3, Car 1, Caspase recruitment domain family, member 15, Caspase recruitment domain protein 15, Caspase recruitment domain-containing protein 15, Cellular tumor antigen p53, Constitutive activator of retinoid response, Constitutive active response, Constitutive androstane receptor, DHTR, DKFZp686N23123, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), ER, ER-alpha, ER-beta, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen-related receptor alpha, Estrra, FLJ11090, FLJ92943, GCCR, GCRST, GCR_HUMAN, GR, Glucocorticoid receptor, Grl1, HDL cholesterol, augmented response of, to hormone replacement, included, HUMARA, HYSP1, IBD1, Inflammatory bowel disease protein 1, KD, Kennedy disease (KD), LFS1, LRR containing protein, MB67, MGC104252, MGC112732, MGC97144, Mutant tumor protein 53, Myocardial infarction, susceptibility to, included, NLR family, CARD domain containing 2, NLRC2, NOD like receptor C2, NOD2 protein, NOD2B, NOD2_HUMAN, NR1B1, NR1I3_HUMAN, NR3A1, NR3A2, NR3B1, NR3C4, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, Nucleotide binding oligomerization domain containing 2, Nucleotide binding oligomerization domain, leucine rich repeat and CARD domain containing 2, Nucleotide-binding oligomerization domain-containing protein 2, OTTHUMP00000017718, OTTHUMP00000017719, Orphan nuclear receptor MB67, Orphan nuclear receptor NR1I3, P53_HUMAN, PFIC 2, PGY4, PSORAS1, Phosphoprotein p53, RAR, RAR-alpha, RARA_HUMAN, RARalpha1, RNESTROR, RP24-311F12.2, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, SBMA, SCAN1, SMAX1, Sister of P glycoprotein, Spgp, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid hormone receptor ERR1, TFM, TRP53, TYDP, TYDP1_HUMAN, Testicular Feminization (TFM), Tp53, Transformation related protein 53, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, androgen receptor splice variant 4b, constitutive active receptor, constitutive androstane nuclear receptor variant 2, constitutive androstane nuclear receptor variant 3, constitutive androstane nuclear receptor variant 4, constitutive androstane nuclear receptor variant 5, estrogen receptor related receptor alpha, glucocorticoid nuclear receptor variant 1, hERR1, nr3c1, nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor), nucleotide binding oligomerization domain 2, orphan nuclear hormone receptor, p53 tumor suppressor, progressive familial intrahepatic cholestasis 2, tumor antigen p55

1 Images
Chemical Structure - Docetaxel, Cytotoxic agent (AB141248)
  • Chemical Structure

Lab

Chemical Structure - Docetaxel, Cytotoxic agent (AB141248)

2D chemical structure image of ab141248, Docetaxel, Cytotoxic agent

Key facts

CAS番号

114977-28-5

精製度

>99%

製品の状態

Solid

form

分子量

807.9 Da

分子式

C<sub>4</sub><sub>3</sub>H<sub>5</sub><sub>3</sub>NO<sub>1</sub><sub>4</sub>

PubChem

148124

由来

Synthetic

溶解性

Soluble in DMSO to 100 mM

Soluble in ethanol to 100 mM

化学名

Docetaxel

生物学的記述

Potent cytotoxic agent in vitro (IC50 = 2 nM). Disrupts microtubule assembly and arrests cell divison at G2/M phase. Induces apoptosis. Antitumor agent. Active in vivo and in vitro.

Canonical smiles

CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O

Isomeric smiles

CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O

InChi

InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1

InChiKey

ZDZOTLJHXYCWBA-VCVYQWHSSA-N

IUPAC名

[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate

出荷温度及び保存条件

出荷温度
Ambient - Can Ship with Ice
短期保存温度
+4°C
長期保存温度
+4°C
保管に関する情報
Store under desiccating conditions|The product can be stored for up to 12 months

Need more advice on solubility, usage and handling? Please visit our our product support page for more details.

|

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

|

Toxic, refer to SDS for further information.

製品プロトコール

文献 (4)

Recent publications for all applications. Explore the full list and refine your search

Naunyn-Schmiedeberg's archives of pharmacology : PubMed40227306

2025

Effects of empagliflozin and its combination with docetaxel on LNCaP and DU- 145 prostate cancer cell lines: cytotoxicity and molecular pathway analysis.

Applications

Unspecified application

Species

Unspecified reactive species

Ahmet Cumaoğlu,Selda Nur Akdeniz,Ahmad Karzoon,Mohamed Alaama,Mükerrem Betül Yerer

Therapeutic advances in urology 12:1756287220927994 PubMed35173811

2020

The effects of docetaxel and/or captopril in expression of TGF-β1, MMP-1, CTGF, and PAI-1 as markers of anterior urethral stricture in an animal model.

Applications

Unspecified application

Species

Unspecified reactive species

Wikan Kurniawan,Marsetyawan Heparis Nur Ekandaru Soesatyo,Teguh Aryandono

EMBO molecular medicine 11:e11031 PubMed31512803

2019

CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia.

Applications

Unspecified application

Species

Unspecified reactive species

Talveen S Purba,Kayumba Ng'andu,Lars Brunken,Eleanor Smart,Ellen Mitchell,Nashat Hassan,Aaron O'Brien,Charlotte Mellor,Jennifer Jackson,Asim Shahmalak,Ralf Paus

Theranostics 8:109-123 PubMed29290796

2018

PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.

Applications

Unspecified application

Species

Unspecified reactive species

Jin Zeng,Wei Liu,Yi-Zeng Fan,Da-Lin He,Lei Li
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com